Enhertu launched as gastric cancer tertiary treatment in Korea, insurance benefits loading

2 February 2023 - In an environment where gastric cancer treatments are currently lacking, the approval of Enhertu (ingredient: trastuzumab ...

Read more →

Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan

2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...

Read more →

Nintedanib esylate for the treatment of adults with idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis ...

Read more →

Somatrogon for treating growth disturbance in people 3 years and over

1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...

Read more →

Trastuzumab deruxtecan for treating HER2 positive unresectable or metastatic breast cancer after one or more anti-HER2 treatments

1 February 2023 - Trastuzumab deruxtecan is recommended with managed access as an option for the treatment of adults with HER2 ...

Read more →

Upadacitinib monohydrate for the treatment of patients with active non-radiographic axial spondyloarthritis

1 February 2023 - Upadacitinib monohydrate is recommended as an option for the treatment of adults with active non-radiographic axial ...

Read more →

Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England

31 January 2023 - Jazz Pharmaceuticals today announced that Epidyolex (cannabidiol 100 mg/mL oral solution), developed by GW Pharmaceuticals, has been ...

Read more →

Highlights from the CHMP 23-26 January 2023 meeting

27 January 2023 - Four new medicines recommended for approval. ...

Read more →

Dupixent (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

27 January 2023 - Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent ...

Read more →

Recommendations made by the PBAC – December 2022 intracycle meeting

27 January 2023 - Recommendations made by the PBAC in December 2022 relating to the listing of drugs on the PBS ...

Read more →

Risankizumab for the treatment of patients with previously treated moderate to severe active Crohn's disease

27 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using risankizumab in ...

Read more →

MSAC publishes agenda for April 2023 PASC meeting

27 January 2023 - The MSAC Secretariat has published a list of applications scheduled to be considered by the PICO Advisory ...

Read more →

New atopic dermatitis drugs for young patients to get expanded coverage

26 January 2023 - As the Government moves toward expanding insurance coverage for atopic dermatitis from adult to children and ...

Read more →

Draft methods (version 7.0): IQWiG is extending the comment period

26 January 2023 - The new deadline is 28 February 2023. ...

Read more →

More than 400 people set to benefit after NICE approves ground-breaking CAR-T therapy to treat aggressive form of blood cancer

26 January 2023 - Hundreds of people with an aggressive form of lymphoma are set to benefit from the first ...

Read more →